$MCK

Lau Michele sold $2.7M of MCK

Lau Michele (EVP and Chief Legal Officer) sold 3,550 shares of MCKESSON CORP (MCK) at $761.09 ($2.70M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lau Michele
Published May 27, 2026, 6:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

Because the trade is pre-scheduled, it is less likely to be a real-time signal about near-term fundamentals; expect muted market reaction absent other news.

02

Market read

Insider selling disclosure with 10b5-1 reduces catalyst value; likely limited trading impact for MCK.

03

What to watch

The sale size ($2.70M) and post-transaction holdings (3,247 shares) may be consistent with routine diversification rather than a thesis change.

Relevance 7/10Timing: Immediate (filed today) but informationally limited; more useful for monitoring insider activity trends than for catalysts.

Background

SEC Form 4 reports insider trades; this one is an open-market sale by McKesson’s EVP and Chief Legal Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson disclosed an EVP/Chief Legal Officer open-market sale of 3,550 shares ($2.70M) under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely noise unless accompanied by other fundamental news.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which generally reduces interpretive value for near-term price direction.

Market effects

Minimal; this is company-specific insider liquidity/compensation activity with no stated operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still reflect internal caution; traders may watch for clustering of sales around specific events.

Key entities

  • MCKESSON CORP

    Subject of the Form 4 insider transaction disclosure.

  • Lau Michele

    EVP and Chief Legal Officer who sold 3,550 shares under a 10b5-1 plan.

Related articles

$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.